text-only page produced automatically by LIFT Text Transcoder Skip all navigation and go to page contentSkip top navigation and go to directorate navigationSkip top navigation and go to page navigation
National Science Foundation
Search  
Awards
design element
Search Awards
Recent Awards
Presidential and Honorary Awards
About Awards
Grant Policy Manual
Grant General Conditions
Cooperative Agreement Conditions
Special Conditions
Federal Demonstration Partnership
Policy Office Website


Award Abstract #0540710
Altitude Symptoms at the South Pole


NSF Org: ANT
Antarctic Sciences Division
divider line
divider line
Initial Amendment Date: September 19, 2006
divider line
Latest Amendment Date: May 27, 2009
divider line
Award Number: 0540710
divider line
Award Instrument: Continuing grant
divider line
Program Manager: Roberta L. Marinelli
ANT Antarctic Sciences Division
OPP Office of Polar Programs
divider line
Start Date: October 1, 2006
divider line
Expires: September 30, 2010 (Estimated)
divider line
Awarded Amount to Date: $396491
divider line
Investigator(s): Bruce Johnson johnson.bruce@mayo.edu (Principal Investigator)
Stephen Turner (Co-Principal Investigator)
Kenneth Beck (Co-Principal Investigator)
Kent Bailey (Co-Principal Investigator)
James Hickman (Co-Principal Investigator)
divider line
Sponsor: Mayo Clinic Rochester
200 First Street South West
Rochester, MN 55905 507/284-2220
divider line
NSF Program(s): HEALTH,
ANTARCTIC ORGANISMS & ECOSYST
divider line
Field Application(s): 0116000 Human Subjects,
0311000 Polar Programs-Related
divider line
Program Reference Code(s): OTHR, EGCH, 9169, 0000
divider line
Program Element Code(s): 5189, 5111

ABSTRACT

The central theme of this proposal is to better understand mechanisms of altitude related illness, to develop demographic, biochemical (serum and plasma), and genetic predictors (or combinations of predictors) of who may be most susceptible to altitude sickness as well as to develop protocols to help optimize acclimatization practice. The adaptive and/or maladaptive processes that lead to altitude-related symptoms (mild to severe) remain obscure and no clear predictors of illness have been found other than the rate of ascent, the altitude of exposure and activity level at altitude. Two specific aims will be pursued over the proposed 3 years of study. The first is to quantify the incidence, timing, severity and duration of altitude symptoms at the South Pole. Symptoms will be assessed at sea level (McMurdo Station) and at 6 time periods while at altitude to follow the time course of symptom resolution. In a subgroup of subjects, the current practice of prophylactic use of Acetazolamide will be assessed in a placebo controlled fashion. The second aim is to determine the incremental value of baseline demographic characteristics, biochemical measures (serum and plasma), nighttime physiological monitoring (quantification of oxygen saturation, heart rate variability and respiration) and candidate gene polymorphisms on the ability to predict symptoms of altitude illness. Biochemical markers and candidate genes will be those directly influencing the ventilatory drive, vascular tone, vascular and tissue fluid regulation, inflammation and oxygen carrying capacity of the blood, including peptide hormones and autocoids (or the genes that encode such proteins or their receptors). In a subgroup of more symptomatic subjects and relatively asymptomatic subjects, gene expression studies will be performed on peripheral blood mononuclear cells to help guide the choice of candidate genes, which may increase or decrease susceptibility to altitude symptoms. The research will focus on the mild to moderate symptoms often experienced with acute exposure to moderate altitude. Results from this study will help identify personnel (through the development of algorithms) that may be at increased risk for developing more severe altitude symptoms (and therefore may require more effective preventive measures) and improve current altitude-illness preventive procedures at South Pole. Findings will also be applicable to the general population (altitude sojourners), to commercial air travel (pressurized to low to moderate altitudes), the space program (long term space flight at reduced atmospheric pressures) and may provide insight into clinical pathologies that result in low oxygen tensions in the blood or tissues (e.g., lung disease, obstructive sleep apnea and heart failure). As a part of this project, a web site will be developed that links with local secondary school programs as well as mountaineering and clinical web sites that inform students, climbers and the general population about altitude-related illness. In addition, with the help of secondary school teachers, a curriculum will be developed on altitude adaptation, symptoms and prevention.

 

Please report errors in award information by writing to: awardsearch@nsf.gov.

 

 

Print this page
Back to Top of page
  Web Policies and Important Links | Privacy | FOIA | Help | Contact NSF | Contact Web Master | SiteMap  
National Science Foundation
The National Science Foundation, 4201 Wilson Boulevard, Arlington, Virginia 22230, USA
Tel: (703) 292-5111, FIRS: (800) 877-8339 | TDD: (800) 281-8749
Last Updated:
April 2, 2007
Text Only


Last Updated:April 2, 2007